Mobile

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Coli...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002782-32

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary Objective for the Induction Phase • To determine the effect of MLN0002 induction treatment on clinical response at 6 weeks Primary Objective for the Maintenance Phase • To determine the effect of MLN0002 maintenance treatment on clinical remission at 52 weeks

Critère d'inclusion

  • Moderate to severe Ulcerative Colitis

Liens